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The tyrosine kinase inhibitor imatinib (STI571, Gleevec;
Novartis), administered at 400 mg daily, is the standard front-
line therapy for patients with chronic myeloid leukemia
(CML) in chronic phase.1-3 This molecularly targeted therapy
leads to a dramatic clinical response: the International
Randomized Study of Interferon Versus STI571 (IRIS) trial
showed that 82% of patients achieved a complete cytogenet-
ic response.4 However, a substantial fraction of patients devel-
ops acquired resistance to imatinib.5-7 In order to improve the
outcome of patients with early chronic-phase CML, several
phase II clinical trials were conducted at the MD Anderson
Cancer Center to investigate the treatment effects of new
strategies: front-line treatment with high-dose imatinib (800
mg daily) as well as with the second-generation tyrosine
kinase inhibitors dasatinib and nilotinib.8,9 Results from these
studies suggested the superiority of the use of dasatinib and
nilotinib over standard imatinib therapy as front-line treat-
ment. Both dasatinib and nilotinib induced a 98% complete
cytogenetic response rate in patients treated for at least 3
months, with nearly 90% of patients achieving complete
cytogenetic response by 3 months of therapy.4,8,9 Furthermore,
randomized phase III trials have demonstrated improved
response rates and decreased rates of transformation in
patients treated with nilotinib or dasatinib compared to the
rates in patients treated with imatinib.10-12 In addition, these
tyrosine kinase inhibitors are more potent as inhibitors of the
kinase activity of BCR-ABL1 and overcome the resistance
imposed by most BCR-ABL1 mutants identified in patients
with CML in whom imatinib therapy fails. When nilotinib or
dasatinib is used after failure of imatinib therapy, these agents
induce complete cytogenetic responses in approximately
50% of patients.13-16
Despite the demonstrated superiority of the second-gener-
ation tyrosine kinase inhibitors as front-line therapy, several
critical questions remain. For instance, the differential effects
of dasatinib, nilotinib and high-dose imatinib on different
subpopulations of CML cells are incompletely understood.
We have previously addressed this question utilizing data
from patients treated front-line with low-dose imatinib.17,18
Furthermore, the ability of these agents to eliminate minimal
residual disease remains to be demonstrated. Here we utilized
datasets of patients with CML treated in several phase II stud-
ies to discern potential differences in the dynamics of molec-
ular responses to second-generation tyrosine kinase inhibitors
or high-dose imatinib in the context of front-line and post-
imatinib failure settings. Our efforts include the development
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Treatment with the tyrosine kinase inhibitor imatinib is the standard of care for newly diagnosed patients with
chronic myeloid leukemia. In recent years, several second-generation inhibitors – such as dasatinib and nilotinib –
have become available: these promise to overcome some of the mutations associated with acquired resistance to
imatinib. Despite eliciting similar clinical responses, the molecular effects of these agents on different subpopula-
tions of leukemic cells remain incompletely understood. Furthermore, the consequences of using high-dose ima-
tinib therapy have not been investigated in detail. Here we utilized clinical data from patients treated with dasa-
tinib, nilotinib, or high-dose imatinib, together with a statistical data analysis and mathematical modeling
approach, to investigate the molecular treatment response of leukemic cells to these agents. We found that these
drugs elicit very similar responses if administered front-line. However, patients display significantly different
kinetics when treated second-line, both in terms of differences between front-line and second-line treatment for
the same drug, and among agents when used as second-line. We then utilized a mathematical framework describ-
ing the behavior of four differentiation levels of leukemic cells during therapy to predict the treatment response
kinetics for the different cohorts of patients. The dynamics of BCR-ABL1 clearance observed in our study suggest
that the use of standard or high-dose imatinib or a second-generation tyrosine kinase inhibitor such as nilotinib or
dasatinib elicits similar responses when administered as front-line therapy for patients with chronic myeloid
leukemia in chronic phase.
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ABSTRACT
of a statistical model that gives a good, low-dimensional
representation of the time courses and a mathematical
model that estimates biologically interesting parameters.
The parameters of these models were then compared
between treatments strategies. This approach is useful for
understanding the effects of different tyrosine kinase
inhibitors on individual cell populations and can also be
applied to other cancer types treated with targeted agents.
Methods
Study population and data collection 
A total of 290 patients with CML treated front-line or second-
line with tyrosine kinase inhibitors were investigated. These
patients comprised 92 treated with dasatinib, 75 treated with nilo-
tinib, and 123 treated with high-dose imatinib. All imatinib-treat-
ed patients were treated front-line, i.e. immediately after diagnosis
of the disease, while 23 dasatinib–treated and 24 nilotinib-treated
patients were administered the respective drug as second-line ther-
apy after progression of disease. All patients received these agents
in phase II studies8,9 at the MD Anderson Cancer Center.  Fourteen
of the 243 patients treated front-line and 16 of the 47 treated sec-
ond-line had accelerated phase disease based exclusively on the
presence of clonal evolution; the remaining patients were in
chronic phase. The assignment of treatment was not done in a ran-
domized fashion; the studies with imatinib and high-dose ima-
tinib were conducted in a sequential fashion. Subsequently, both
phase II studies using either nilotinib or dasatinib as front-line
therapy were conducted in parallel and superseded the study with
high-dose imatinib. While patients were not assigned to the latter
phase 2 studies in a randomized fashion, they were distributed
between both studies so as to sustain a similar rate of accrual.
The levels of BCR-ABL1 transcripts in peripheral blood samples
were measured by quantitative real-time polymerase chain reac-
tion. The ratio of BCR-ABL1 to the control gene ABL1 was deter-
mined. BCR-ABL1/ABL1 ratios are expressed in accordance with
the International Scale. Patients’ samples were obtained to deter-
mine the BCR-ABL1/ABL1 ratio ideally at 0, 3, 6, 9, 12, 18, and 24
months after initiation of therapy. All 290 patients had measure-
ments at the first five time points. Overall, 32 (11%) patients had
five measurements, 41 (14%) patients had six measurements, and
217 (75%) patients had all seven measurements.
A second set of 13 patients treated with standard-dose imatinib
(400 mg daily) from the IRIS trial was included as a control and
analysed using the same methodology. We utilized only measure-
ments made at 0, 3, 6, 9, 12, 18, and 24 months after initiation of
therapy for this analysis. The 15- and 21-month measurements as
well as measurements after the 24th month (if any) were neglected
to make the data sets comparable. Importantly, only patients with
measurements at the first five time points were included.
Data were analyzed using two types of models. The first was a
statistical model described in the following part of the manuscript.
The second was a mathematical model described partly after the
statistical model and partly in the Online Supplement. All analyses
were conducted in R. Statistical tests with corresponding P values
less than 0.05 were considered significant.
Results
To investigate the time courses of BCR-ABL1 transcript
levels, we first designed a statistical model with the pri-
mary goal of finding the best fit to the data with minimal
assumptions. We chose a low-dimensional model in our
statistical approach because we sought to obtain simple
summaries of the time courses. In addition, since there
were at most seven measurements per patient, the data
supported only a low-dimensional model. As a first step,
we used the natural logarithm to transform our data, since
the measurements were on vastly different scales. We
added 1 to the observed data before transformation since
some of the measured transcript levels were 0. Our initial
model on the transformed data was bi-exponential, which
is the sum of two scaled exponentials, and is traditional for
modeling exponentially-decaying data.19 Such a model
contains four parameters per subject, which were consid-
ered to be too many. As shown in Online Supplementary
Figure S1, we found that one of the exponentials could be
replaced with a constant, which saved a parameter with
little reduction in goodness of fit. To save additional
degrees of freedom, we examined models that represented
aspects of the times courses that were common across
subjects. Our resulting model for the ith subject at time t
was given by yit = α0i + α1i exp[-βt] + εit, where α0i was the
subject-specific intercept, α1i was the subject-specific
slope, β was the population-based shape parameter and εit
were independent, identically distributed mean 0 errors.
In other words, α0i was the patient-specific amount by
which the exponential curve was offset from 0, α1i was the
patient-specific magnitude by which the exponential
curve was multiplied, and β was the common value across
all patients that determined the shape of the exponential
curve, with larger values implying faster decreases. We did
not consider patient-specific β values because we wanted
a low-dimensional model and because trying to estimate
them would have introduced identifiability issues. We
then developed an iterative procedure to fit the model to
the data. We obtained an initial estimate of β after merg-
ing all data from all subjects using non-linear least squares.
With β fixed, we then estimated the subject-specific
parameters (α0i and α1i) using traditional least squares. We
iterated between estimating the population parameter and
the subject-specific parameters until convergence. A z-test
was used to test differences in the population parameters
between treatment groups.
Estimates of α0i and α1 for subjects were treated as data
for further analysis. These estimates were correlated with
each other, so joint modeling was necessary. Specifically,
multivariate analysis of variance (MANOVA),20 an exten-
sion of univariate analysis of variance (ANOVA), was used
with treatment drug, front-line or second-line status of the
drug, and stage as independent variables and α0 and α1 as
dependent variables. Significance was assessed using the
Wilks test. Because the dependent variables were not
jointly Gaussian, inference was based on 10,000 permuta-
tions of the independent variables. The variable that was
permuted (treatment, line, or stage) corresponded to the
variable on which inference was made.  
Once we had decided on our model, the primary analy-
sis tested whether the subject-specific parameters were
equal, first three-way and then pairwise. Subsequent
analyses compared front-line to second-line treatment and
chronic to accelerated phase within the dasatinib and nilo-
tinib cohorts and the whole set of hypotheses on only the
set of typical curves.
We fitted the exponential model described above to the
transcript levels of 290 CML patients. The means for the
ratios for time points 0, 3, 6, 9, 12, 18, and 24 months after
initiation of therapy were 28.4, 4.3, 2.1, 0.7, 2.6, 1.8, and
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0.8. We first fitted the model separately for patients treat-
ed with dasatinib, nilotinib or high-dose imatinib. Note
that this investigation utilizes data of patients treated first-
line as well as patients treated second-line; we present the
analysis for subcohorts later. We estimated the population
parameter β as 0.69 for dasatinib-treated patients, 0.65 for
nilotinib-treated patients and 0.62 for the patients treated
with high-dose imatinib. Recall that β represents the com-
mon value that determined the shape of the exponential
curve, with larger values implying faster decreases. These
parameter estimates were not significantly different in any
pairwise comparison between the treatment groups
(P=0.84 for high-dose imatinib versus nilotinib; P=0.58 for
high-dose imatinib versus dasatinib; P=0.85 nilotinib versus
dasatinib). Therefore, we concluded that a single popula-
tion parameter β, which represents the rate of exponential
depletion of BCR-ABL1 values over time, could accurately
represent the curves across treatment groups. To estimate
this single β, we combined all data across groups and fitted
the exponential model again. The resulting β was 0.65.
The model fitted the data well for all three treatment
groups, with a median R2 of 0.96 for each. The fits, shown
in Figures 1-3, were the basis for further analyses.  There
are cases shown in Figure 3 that do not follow our expo-
nential model; the repetition of the analysis without such
cases is discussed later. 
The subject-specific intercept (α0) and slope (α1) values
from the combined fit were dependent variables in
MANOVA models; these models examined whether there
were independent variables with which the dependent
variables were associated. Results are displayed in Table 1.
Recall that α0i represents the patient-specific amount by
which the exponential curve was offset from 0, and α1i
was the patient-specific magnitude by which the expo-
nential curve was multiplied. A three-way comparison
among the treatment groups was significant (P=0.004), so
the hypothesis that the subject-specific parameters were
the same across groups was rejected. Pairwise compar-
isons between treatment groups showed no significant
difference between high-dose imatinib and dasatinib
(P=0.14). However, they did show a significant difference
between imatinib and nilotinib (P=0.001) and between
nilotinib and dasatinib (P<0.001). The average intercept
for nilotinib-treated patients was higher (0.52 versus 0.29)
and the average slope was lower (2.34 versus 2.51) relative
to those for the dasatinib-treated patients. Note that these
results were obtained when analyzing patients treated
front-line or second-line. When analyzing only the
patients treated front-line, the three-way comparison
among treatments was not significant (P=0.72). However,
front-line versus second-line status led to significantly dif-
ferent results (P<0.001). Here patients treated front-line
had a lower average intercept (0.14 versus 1.04) and a high-
er average slope (2.70 versus 1.44) than patients given the
tyrosine kinase inhibitor as second-line treatment. Within
the dasatinib and nilotinib cohorts, front-line was signifi-
cantly different than second-line (P<0.001 for both).  The
directions of slope and intercept were the same as in the
merged front-line and second-line groups. 
Overall, there were no significant pairwise differences
between treatment groups within the front-line or within
the second-line cohorts. While there was a significant dif-
Dynamic of CML response to TKI
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Figure 1. The high-dose
imatinib cohort. The fig-
ure shows data from
four representative
patients from the high-
dose imatinib cohort,
displaying the ratio of
BCR-ABL1 to ABL1 plus
one over time measured
in months (broken line)
as well as the exponen-
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ference between chronic and accelerated phase (P<0.001),
there was no significant difference between stages when
analyzing only patients treated front-line. A bivariate
model with both treatment and front-line status was sig-
nificant for both variables, indicating treatment and front-
line status were independent prognostic factors.  
Based on the preceding analysis, we drew a few conclu-
sions. First, the shape of the curves was similar across
treatment groups. Second, the driver of the difference
between curves was front-line versus second-line status.
The front-line curves tended to have lower intercepts but
higher scale factors. Third, after taking into account front-
line versus second-line status, there was still an impact of
treatment.  
We also conducted a similar analysis on the cohort of
patients treated with 400 mg imatinib. Here the popula-
tion parameter β was taken from the earlier three-group
analysis and the subject-specific parameters were com-
pared. The four-way comparison among groups was again
statistically significant (P<0.001). Pairwise comparisons
between each of the three groups and standard-dose ima-
tinib were all statistically significant. 
We next explored the robustness of our modeling.
There were two main ways in which a subset of curves
differed from the typical exponential pattern. Some curves
increased over a portion of the time interval, rather than
decreasing or staying level. Other curves showed low val-
ues throughout. To identify the increasing curves, we used
the heuristic of two measurements in the log-transformed
data that were more than one unit above the previously
observed minimum. The reason for choosing this criterion
was that small increases were possible due to random
variation in small values. In addition, occasional faulty
measurements were possible. There were 22 (7.6%) such
increasing curves. The percentages by treatment groups
were 3.3% for the patients treated with high-dose ima-
tinib, 8.7% for those treated with nilotinib, and 13.3% for
the patients treated with dasatinib. Pairwise, the only sig-
nificant difference in percentages was between high-dose
imatinib- and dasatinib-treated patients (P=0.01). Among
the patients treated front-line, 3.3% had increasing values,
while among the patients treated second-line, 29.8% had
increasing values. This difference was statistically signifi-
cant (P<0.001).  
Low value curves were those with maximum values less
than one in the log-transformed data. There were 22 sam-
ples (7.6%) of this type. The percentages were 6.5% for
imatinib-, 8.0% for nilotinib-, and 8.7% for dasatinib-
treated patients. None of these percentages was signifi-
cantly different from each other by pairwise comparison.
These percentages were 7.4% for front-line treatment and
8.5% for second-line treatment, which were again not sig-
nificantly different.
The analyses above were repeated on just the patients
treated at the MD Anderson Cancer Center with the
increasing and low value curves eliminated. This approach
left 246 out of the original 290 patients. The population
parameter β was again not significantly different among
treatment groups based on pairwise comparison, so a sin-
gle model was fitted to all curves. For the MANOVA
A. Olshen et al.
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Figure 2. The nilotinib
cohort. The figure
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model, the three-way comparison among the treatment
groups was only borderline significant (P=0.06). Pairwise
differences this time were all not significant. The three-
way comparison for just the patients treated front-line
was again not significant (P=0.38). Front-line versus sec-
ond-line status was again significant when comparing all
patients or only within nilotinib- or dasatinib-treated
patients (P<0.001 for all three). The bivariate model with
both treatment and front-line status was again significant
for both variables, indicating that treatment and front-line
status were independent prognostic factors. Overall, the
results were robust to inclusion or exclusion of atypical
curves.  
We then utilized a previously designed mathematical
model describing the differentiation hierarchy of
hematopoietic cells17,18 to analyze the data. This model
was created to relate the available data on BCR-ABL1 tran-
script levels in peripheral blood to the kinetics of other,
unobservable levels of differentiation of leukemic cells.
Through this model, we thus aimed to investigate the
underlying mechanism of treatment response by studying
the different response kinetics of separate leukemic sub-
populations. In the context of this model, stem cells on top
of the hierarchy give rise to progenitor cells, which pro-
duce differentiated cells, which in turn produce terminally
differentiated cells. This differentiation hierarchy applies
to normal and leukemic cells. The model assumes that the
BCR-ABL1 oncogene increases the rate at which progeni-
tors and differentiated cells are being produced.
Molecularly targeted therapy counteracts the effects of
BCR-ABL1 by reducing the differentiation rates and possi-
bly reducing the growth rate of leukemic stem cells. The
basic model together with a description of the parameters
is provided in Online Supplementary Table S1. 
This model represents the four kinetically dominant
subpopulations in the hematopoietic differentiation hier-
archy; in reality, this hierarchy includes a larger number of
distinct differentiation levels. However, for the purposes
of explaining the dynamics of response to tyrosine kinase
inhibitors, only four populations need to be included in a
mathematical model since they are the kinetically domi-
nant populations. Similarly, if each subpopulation consists
of many clones of the same differentiation stage, which
may have distinct growth, differentiation, and death
kinetics, then the predictions of the model with regard to
the question addressed in this paper does not change. The
model then describes the dominant clone within the
respective subpopulation at any given time. 
To investigate the parameters of the mathematical
model, we again utilized the data of newly diagnosed
patients who were treated with front-line dasatinib, nilo-
tinib or imatinib (800 mg or 400 mg daily) outlined above.
Any value of zero, i.e. any value below the detection base-
line of the polymerase chain reaction assay, was replaced
with 0.00001. The replacement value of 0.00001 was cho-
sen because the minimum value in the data was 0.00004.
This replacement was needed for the logarithmic transfor-
mation and is consistent with the previous use of this
model.18 We later conducted sensitivity analyses on the
choice of this replacement value using 0.00002 and
0.000005 and obtained consistent conclusions. For each
treatment cohort, we investigated two models and select-
Dynamic of CML response to TKI
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Figure 3. The dasatinib
cohort. The figure
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ed the one that best fitted the data using R2 and a permu-
tation test. The two models analyzed were: (i) an expo-
nential model, which predicts that the leukemic cell bur-
den declines at a single exponential rate; and (ii) a bi-pha-
sic exponential model, which predicts that the BCR-
ABL1/ABL1 ratio declines according to two exponential
slopes with a turning point.17,18 The estimated slopes were
then incorporated into our mathematical framework to
predict the dynamics of treatment responses in the four
cohorts. Note that the model fitting and R2 calculation
used the logarithmically transformed data (Online
Supplementary Information). Once we decided on our
model, the primary analysis tested whether the estimated
slopes were equal, first three-way and then pairwise.
When applying this approach to our cohorts of CML
patients, we found that the bi-phasic exponential model
was the better fitting of our two models for all four
cohorts (Online Supplementary Table S2). Besides the analy-
sis of the entire cohort, we also performed individual
model fitting to compare, for each individual patient, the
fit of the single-phasic and bi-phasic exponential models.
Based on the permutation test procedure (using the join-
point software, http://surveillance.cancer.gov/joinpoint/), we
obtained a better fit of the bi-phasic model for 35 out of
the 69 patients in the dasatinib cohort, 26 out of the 51
patients in the nilotinib cohort, 54 out of the 123 patients
in the high-dose imatinib cohort, and for all 13 patients in
the standard-dose imatinib cohort (Online Supplementary
Table S3). The first and second slopes of depletion as well
as the turning point for the bi-phasic patients in the four
cohorts are summarized in Table 2.
There was no significant difference in the number of
patients exhibiting single-phasic versus bi-phasic trends
among the dasatinib, nilotinib and high-dose imatinib
cohorts (Fisher exact test, P=0.55 for the three-way com-
parison, P values for pairwise comparisons were 1, 0.37,
and 0.41, respectively) (Online Supplementary Table S3).
The differences in the trend were significant for pairwise
comparison of the low-dose imatinib cohort with the
dasatinib, nilotinib and high-dose imatinib cohorts (Fisher
exact test, P=5x10-4, P=9x10-4, P=5x10-5, respectively).
For patients with the bi-phasic model as better fitting in
the dasatinib, nilotinib and 800 mg imatinib cohorts, there
was no significant difference in the number of
positive/negative/zero second slopes (Fisher exact test,
P=0.85 for the three-way comparison, P values for the
pairwise comparisons were 0.79, 0.58, and 0.94 respec-
tively) (Online Supplementary Table S3). The differences
were significant when performing pairwise comparisons
between the cohorts treated with 400 mg imatinib or
dasatinib, and between the cohorts treated with nilotinib
or 800 mg imatinib (Fisher exact test, P=0.025, P=0.028,
and P=0.009, respectively).
There were 35 patients in the dasatinib cohort, 26 in the
nilotinib cohort, 54 in the high-dose imatinib cohort and
13 patients in the low-dose imatinib cohort in whom the
bi-phasic model was the better fitting model and for
whom the first slopes were negative (Online Supplementary
Table S3). There was no significant difference in the first
slope among the four cohorts when applying the
Wilcoxon test in a pairwise manner. Regarding the second
slopes, the number of bi-phasic patients with both nega-
tive first and second slopes was 18 for the dasatinib
cohort, 13 for the nilotinib cohort, 24 for the high-dose
imatinib cohort and 12 for the 400 mg imatinib cohort
(Online Supplementary Table S3). For the three cohorts
(dasatinib, nilotinib and 800 mg imatinib) from MD
Anderson, there was no significant difference in the sec-
ond slope among them. However, there was a significant
difference in second slopes between the 400 mg imatinib
cohort and all three other cohorts. There was a significant
difference in turning points only between the nilotinib
cohort and the 800 mg imatinib cohort. 
We then incorporated the estimated first and second
slopes into our mathematical framework to investigate the
dynamics of treatment responses of the four cohorts. We
found that the framework accurately predicted the
dynamics of treatment responses of all cohorts (Figure 4).
These findings suggest that a model based on four distinct
subpopulations of cells within the differentiation hierar-
chy can accurately explain the treatment responses not
only to first-line, low-dose imatinib, but also to second-
A. Olshen et al.
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Table 1. Comparison of intercepts α0 and slopes α1 in the statistical model for treatment groups, front-line versus second-line, as well as CML
stages. 
Number of patients Intercept mean (SD) Slope mean (SD) P value (comparison)
Treatment type
Imatinib 123 0.14(0.42) 2.59(1.24) 0.08 (imatinib vs. nilotinib)
Nilotinib 75 0.52(1.01) 2.34(1.67) 0.23 (imatinib vs. dasatinib)
Dasatinib 92 0.29(0.56) 2.51(1.44) <0.001 (dasatinib vs. nilotinib)
Previously treated versus treatment-naïve patients
Front-line 243 0.14(0.41) 2.7(1.31) <0.001 (front-line vs. second-line)
Second-line 47 1.04(1.14) 1.44(1.53)
Treatment type for patients treated front-line
Imatinib 123 0.14(0.42) 2.59(1.24) 0.97 (imatinib vs. nilotinib)
Nilotinib 51 0.13(0.38) 2.81(1.44) 0.43 (imatinib vs. dasatinib)
Dasatinib 69 0.14(0.42) 2.82(1.34) 0.60 (dasatinib vs. nilotinib)
Treatment type for patients treated second-line
Nilotinib 24 1.35(1.38) 1.34(1.70) 0.15
Dasatinib 23 0.73(0.70) 1.55(1.35)
CML stage
Chronic 260 0.23(0.59) 2.57(1.39) <0.001
Accelerated 30 0.74(1.12) 1.85(1.54)
line treatment as well as therapy with second-generation
tyrosine kinase inhibitors. This model will be useful for
analyzing long-term treatment responses as more data
become available.  
Discussion
We have presented a quantitative approach to model
the time course of BCR-ABL1 transcripts in patients with
CML. We first designed a statistical model using minimal
assumptions to provide maximal generalizability and
information retrieval from the data. This model provided
information on the shape of the treatment response curves
as well as differences between and among cohorts of
patients. We then utilized a mathematical model empha-
sizing the biological interpretability of the parameters.
This model considers four distinct cell populations within
the differentiation hierarchy of the leukemia and can be
used to predict the treatment response for different
cohorts of patients. 
Our approach demonstrated that dasatinib, nilotinib
and high-dose imatinib elicit very similar treatment
responses in patients treated first-line with these tyrosine
kinase inhibitors. These patterns include decreases in
BCR-ABL1 transcripts in two phases during short-term
treatment. The main result from the statistical model was
a difference between dasatinib and nilotinib only when
including front-line and second-line patients. When com-
paring the 400 mg imatinib cohort from the IRIS trial with
the three cohorts from the MD Anderson Cancer Center
in a pairwise manner, there were significant differences in
phase trends and second slopes. 
However, there were a number of limitations to our
study.  The set of data from the IRIS trial was much small-
er than the datasets obtained from the MD Anderson
patients and the data were generated at different geo-
graphical sites. Furthermore, with the exception of the
nilotinib and dasatinib datasets, which were derived from
two parallel phase II clinical trials, the data were not con-
temporaneous with each other nor were they obtained
from a randomized study. In addition, the low-dose ima-
tinib cohort contained a small number of patients who tol-
erated the treatment for up to 10 years, which might lead
to the analysis of a very selected subgroup of patients.  For
the MD Anderson patients, there was not a significant dif-
ference among treatment groups by age (P=0.53; Kruskal-
Wallis test) or by percentage in chronic phase (P=0.09;
Fisher exact test). Another limitation of the analysis was
the limited number of data points (between 5 and 7) for
each individual subject. A final limitation was that multi-
ple analyses were performed. The nature of these analyses
(some of them were multiple treatment comparisons and
some were subset analyses) makes it difficult to control
the family-wise error rate. However, even in randomized
trials it is rare to see an adjustment for subgroup analyses,
so we believe that our approach is valid.
These caveats notwithstanding, and in concert with the
results herein reported, in the setting of front-line therapy,
treatment with the second-generation tyrosine kinase
inhibitors nilotinib and dasatinib has been shown in ran-
domized phase III studies (i.e. the ENESTnd and DASISION
studies) to produce remarkably better response rates than
standard-dose imatinib.10-12 However, results from the TOPS
study, a phase III randomized study comparing the efficacy
of high-dose imatinib and standard-dose imatinib, resulted
in similar outcomes in both arms of the study.21 A potential
explanation for this discrepancy is the fact that in the TOPS
study, a higher proportion of patients receiving high-dose
imatinib had to discontinue therapy with such an approach
due to toxicity, whereas in the ENESTnd and DASISION
studies, the toxicity profiles of nilotinib and dasatinib were
similar to (if not better than) that of imatinib and the drop-
out rates from the study favored the use of the second-gen-
eration tyrosine kinase inhibitors.10-12 It is also worth empha-
sizing that in the TOPS study, patients treated with high-
dose imatinib achieved complete cytogenetic responses and
major molecular responses considerably earlier than those
receiving standard-dose imatinib (6-month complete cyto-
genetic response 57% versus 45% with standard dose;
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Table 2. Summary statistics of slopes and turning points in all four cohorts of
patients. The table displays the first (β1) and second (β2) slopes as well as the
turning points (τ) for all patients in all four cohorts whose treatment response
data displayed a bi-phasic trend and whose first and second slopes were neg-
ative. The unit for slopes is BCR-ABL1/ABL1% per day and the unit for the turn-
ing point is months.
Dasatinib cohort: 35/69 patients had a bi-phasic trend
Slopes and turning points mean median
(standard error) (number of patients)
First slope, β1, for patients with -0.044 (0.027) -0.038 (35)β1 < zero*
Second slope, β2, for all patients 
with β1 < zero* and β2 < zero* -0.002 (0.002) -0.001 (18)
Turning point, τ, for all patients 
with β1 < zero* and β2 < zero* 5.28 (2.01) 4.39 (18)
Nilotinib cohort: 26/51 patients had a bi-phasic trend
Slopes and turning points mean median
(standard error) (number of patients)
First slope, β1, for patients -0.046 (0.016) -0.041 (26)
with β1 < zero*
Second slope, β2, for all patients -0.001 (13) -0.002 (0.002)
with β1 < zero* and β2 < zero*
Turning point, τ, for all patients 4.29 (1.15) 3.90 (13)
with β1 < zero* and β2 < zero*
High-dose imatinib cohort: 54/123 patients had a bi-phasic trend
Slopes and turning points mean median
(standard error) (number of patients)
First slope, β1, for patients -0.044 (0.018) -0.040 (54)
with β1 < zero*
Second slope, β2, for all patients -0.002 (0.001) -0.002 (24)
with β1 < zero* and β2 < zero*
Turning point, τ, for all patients 5.68 (1.79) 5.12 (24)
with β1 < zero* and β2 < zero*
Standard dose imatinib cohort: 13 / 13 patients had a bi-phasic trend
Slopes and turning points mean median
(standard error) (number of patients)
First slope, β1, for patients 
with β1 < zero* -0.037 (0.011) -0.036 (13)
Second slope, β2, for all patients -0.004 (0.002) -0.004 (12)
with β1 < zero* and β2 < zero*
Turning point, τ, for all patients 5.07 (1.46) 4.85 (12)
with β1 < zero* and β2 < zero*
* zero refers to any number with an absolute value ≤ 10–8.
P=0.01) and those receiving high-dose imatinib capable of
maintaining adequate dose intensity had improved out-
comes. A recent study showed higher major molecular
response rates at 12 months among patients receiving high-
dose imatinib than among those receiving standard-dose
imatinib (59% versus 44%, P<0.001) and improved rates of
complete molecular responses by 3 years (57% versus 46%,
respectively).22 These results are important given the favor-
able prognostic impact of achieving early deep molecular
responses shown by different independent studies.23-25 In
contrast to these findings, the dynamics of BCR-ABL1 clear-
ance observed in our study suggest that the use of standard
or high-dose imatinib or a second-generation tyrosine kinase
inhibitor such as nilotinib or dasatinib elicits similar respons-
es when administered as front-line therapy for patients with
CML in chronic phase. The discrepancy between our results
and previous findings might stem from differences in the
selection of patients, an absence of randomization in the
study protocol leading to biases in the MD Anderson
cohorts, and the use of different statistical methods designed
to analyze the shape of the treatment response curves in
detail. In particular, the standard-dose imatinib cohort was
part of the Australasian arm of the IRIS trial and represents
a very selected subgroup of patients – those that tolerated
imatinib for a prolonged period (up to 10 years) without
developing resistance or progression of disease. They might
thus be examples of the best possible response kinetics that
standard-dose imatinib can elicit. Furthermore, the blood
samples of these patients were not analyzed at MD
Anderson, unlike the samples from the remainder of the
patients included in our study. Nevertheless, our results do
not provide evidence against using second-generation tyro-
sine kinase inhibitors as front-line treatment for patients
with chronic phase CML.
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Figure 4. A mathematical framework accurately predicts the dynam-
ics of treatment responses of cohorts of patients treated with dasa-
tinib, nilotinib and high-dose imatinib separately. The panels display
the median (orange circles) and quartiles of the dasatinib, nilotinib
and high-dose imatinib response data together with the results of the
mathematical framework (blue curves, see Online Supplementary
Table S1). (A) Median plots and results of the mathematical frame-
work for the dasatinib response data. (B) Median plots and results of
the mathematical framework for the nilotinib response data. (C)
Median plots and results of the mathematical framework for the
high-dose imatinib response data. Based on the model presented in
the Online Supplement, the mathematical model prediction is given
by y3/(2x3+ y3). Here x3 and y3 denote the abundance of normal and
leukemic terminally differentiated cells. Parameter values are d0 =
0.0005, d3 = 1, rx = 0.008, ry = 0.01, px = 1.5x10-5, py = 1.9x10-6, ax =
0.35, bx = 5.5, cx = 100, ay = 2ax, by = 1.5*bx, cy = cx, c’y = cy, r’y = ry/15.
For the dasatinib cohort, d1 = 0.0053, d2 = 0.0394, a’y = ay/200, b’y =
by/300; for the nilotinib cohort d1 = 0.0028, d2 = 0.0442, a’y = ay/400,
b’y = by/600; for the high-dose imatinib cohort, d1 = 0.0035, d2 =
0.055, a’y = ay/400, b’y = by/600. Apart from the dimension-less
parameters, all values are given in units per day. Note that these
parameter choices represent only one example that can recapitulate
the dynamics of the treatment response seen in the clinic; other
choices are possible.   
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